Skip to content
lifestyle.faithfamilyamerica.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Annovis Bio Inc.
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
August 14, 2026
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
July 7, 2026
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
July 1, 2026
Annovis CEO to Present on Multi-Protein Model of Alzheimer’s Disease at Fierce Biotech Week 2026
May 7, 2026
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio
April 29, 2026
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio
April 29, 2026
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
April 9, 2026
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
April 2, 2026
Annovis Publishes Historical Review of Buntanetap in The Scientist
March 31, 2026
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson’s Disease Study
March 19, 2026
1
2
Next Page
→